BridgeBio signals 3 launches in next 7 months with BBP-418 November 27 PDUFA and infigratinib February 4, 2027 PDUFA
Read original article on Breaking News on Seeking Alpha →Related news
- MPS outlines $8B capacity by 2H 2027 as it raises enterprise data growth floor to 150% Business Corporate
- Alignment targets at least 20% 2027 top-line growth while lowering 2026 adjusted EBITDA outlook to no less than $100M Business Corporate
- First Solar outlines 2027 India output of 2.2-2.6 GW as board authorizes $500M buyback Business Manufacturing India
- Exponent forecasts 2026 net revenue growth of 10%–11% as it raises EBITDA margin outlook to 28%–28.3% Business Corporate
- SPX outlines ~$1.1B data center capacity as 2026 adjusted EBITDA growth guide shifts to ~25% Business Corporate
- Stryker anticipates 6.5% to 7% organic net sales growth in 2026 as it plans to scale Versius in the U.S. Business Corporate
- Dexcom anticipates $5.20B-$5.25B 2026 revenue while authorizing another $1B buyback Business Corporate
-
Hero MotoCorp bets on premiumisation, EVs to sustain growth momentum
Business
Manufacturing
India